On August 11, 2026, a Phase 3 clinical trial listing recorded a recruiting status for a study involving somatropin recombinant. The trial, registered as NCT07221851, is titled "Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders."
The study is designated Phase 3 and is currently in the recruiting stage, according to the registry entry. It is designed to compare a weekly formulation, lonapegsomatropin, against daily somatropin in a pediatric and adolescent population with short stature or growth failure linked to growth hormone sufficient disorders.
No results, efficacy data, or safety findings have been posted for this trial as of the listed date. The registry entry reflects only the trial's design and current recruitment status, not any outcomes. Somatropin recombinant remains classified under unapproved research status in this context.
Readers seeking more background on this compound can consult the compound overview page for additional context.